BioSpace News Archive

Drug Development

Phase III Trial Shows Lilly’s Tirzepatide is Superior to Rival in Type 2 Diabetes

Lilly’s tirzepatide has been proposed as a potentially effective treatment option that may rival the efficacy of semaglutide.

March 4, 2021
·
3 min read
·
Brandon May
Business

COVID-19 News: CureVac Partners with Novartis and More

Distribution and administration of the Johnson & Johnson vaccine began this week. There is also additional COVID-19 news. Here’s a look.

March 4, 2021
·
3 min read
·
Mark Terry
Policy

After Outcry Over Rejected ALS Therapy, FDA Explains Itself

Advocates from the ALS community flooded the FDA with letters, Tweets, emails, videos and other comments expressing their anger over the rejection and the frustration that there are few therapeutics for a disease that is a delayed death sentence.

March 4, 2021
·
3 min read
·
Alex Keown
Business

Riding the Gene Therapy Wave, Biogen Releases Plans for Facility

Biogen plans to build a new gene therapy manufacturing plant in Research Triangle Park, North Carolina. The site is on the company’s manufacturing campus.

March 4, 2021
·
4 min read
·
Mark Terry
Drug Development

Research Roundup: Putting a Number to COVID-19’s Transmissibility and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

March 4, 2021
·
5 min read
·
Mark Terry
FDA

KemPharm Snags Approval for ADHD Prodrug

KemPharm announced this week that the U.S. Food and Drug Administration has approved its novel ADHD drug for use in patients six years and older.

March 4, 2021
·
2 min read
·
Kate Goodwin
BDO Predicts Strong 2021 Biotech Economy, Alongside US Economic Rebound

Biotech is poised to benefit. The industry is coming off a record year for biotech IPOs in terms of numbers of deals, as well as their proceeds.

March 4, 2021
·
3 min read
·
Gail Dutton
Genetown

2020 Was Record-Breaking Year of Funding for Massachusetts Biopharmas

The Massachusetts Biotechnology Council 2020 Biopharma Funding Report released this week shows that biopharma companies within the state’s ecosystem raised $5.8 billion in venture funding, almost twice the $3 billion raised in 2019.

March 4, 2021
·
3 min read
·
Alex Keown
Drug Development

Study: Convalescent Plasma Doesn’t Prevent Progression of COVID-19 in At-Risk People

Another study is adding to a growing body of literature that suggests convalescent plasma from recovered patients with COVID-19 doesn’t prevent further COVID-19 progression in at-risk people who visit the emergency room.

March 4, 2021
·
3 min read
·
Brandon May
Deals

Amgen Snaps Up Five Prime for $1.9 Billion to Bolster Oncology Portfolio

Shares of Five Prime Therapeutics were soaring this morning after Amgen announced it was acquiring the company and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion in cash.

March 4, 2021
·
3 min read
·
Alex Keown